The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …

Purpose Lack of control for timevarying exposures can lead to substantial bias in estimates
of treatment effects. The aim of this study is to provide an overview and guidance on some of …

Objective To identify predictors of 10year Expanded Disability Status Scale (EDSS) change
after treatment initiation in patients with relapseonset multiple sclerosis. Methods Using …

Objective To test the hypothesis that immunotherapy prevents long-term disability in
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 …

Objective Although sodium bicarbonate (SB) solution has been widely used in clinical
practice, its effect on mortality when administered to a large population of patients with …

Randomized controlled clinical trials and real-world observational studies provide
complementary information but with different validity. Some clinical questions (disease …

Background In 2002, the UK's National Institute for Clinical Excellence (NICE) concluded
that interferon beta and glatiramer acetate would be cost effective as disease-modifying …

Little epidemiologic research has focused on pollution-related risks in medically vulnerable
or marginalized groups. Using a nationwide 50% random sample of 2008–2016 Medicare …

Background: This study aimed to investigate whether early unfractionated heparin (UFH)
administration provides a survival advantage for patients with sepsis-induced coagulopathy …

Randomised clinical trials are the primary source of evidence, guiding the use of disease-
modifying drugs in multiple sclerosis. However, the spectrum of questions that can be …